Biocon Biologics Limited has achieved a significant milestone by being recognized as an Asia IP Elite for 2025 by Intellectual Asset Management (IAM), the world's leading intellectual property publication. This prestigious recognition marks the ninth consecutive year that Biocon and Biocon Biologics have appeared on this exclusive list, demonstrating sustained excellence in intellectual property management and value creation.

Recognition Details and Significance

The Asia IP Elite accolade is awarded to a select group of Asia-based organizations that have demonstrated exceptional IP value creation and are considered leaders in the region. The award was presented during IPBC Asia, held in Tokyo from November 18-20, 2025.

Biocon first earned its place on the Asia IP Elite list in 2016, becoming the first and only Indian pharmaceutical company to be featured for its robust IP management and consistent IP value creation. In subsequent years, Biocon Biologics has continued this legacy, with the two entities together being among the few Indian pharmaceutical companies consistently featured on the Asia IP Elite roster.

Leadership Commentary

Shreehas Tambe, CEO & Managing Director of Biocon Biologics, emphasized the significance of this achievement: "Our inclusion in the Asia IP Elite list for 2025 marks the ninth consecutive year that Biocon and Biocon Biologics have appeared on this prestigious list. This reflects our sustained commitment to innovation and strong intellectual property strategy. It reinforces our growing stature as a global biosimilars leader and the role of our IP strategy in expanding access to high-quality, affordable therapies for patients worldwide."

Selection Process and Criteria

Each year, the IAM editorial team conducts an extensive research process, incorporating both quantitative and qualitative analyses, to highlight an exclusive group of leading corporations and research institutions as inductees into the Asia IP Elite. This rigorous evaluation process ensures that only organizations demonstrating exceptional IP management capabilities receive recognition.

Company Profile and Global Reach

Biocon Biologics Limited operates as a unique, fully integrated, global biosimilars company committed to transforming healthcare and transforming lives. The company leverages its lab-to-market capabilities to serve over 6.30 million patients across 120 countries by enabling affordable access to high-quality biosimilars.

The company has commercialized 10 biosimilars from its portfolio, addressing patient needs in key emerging markets and advanced markets. It maintains a pipeline of 20 biosimilar assets across diabetology, oncology, immunology, ophthalmology, bone health, and other non-communicable diseases.

Strategic Impact

This recognition reinforces Biocon Biologics' position as a leader in the global biosimilars industry and validates its intellectual property strategy. The company continues to leverage cutting-edge science, innovative technology platforms, global scale manufacturing capabilities, and world-class quality systems to lower costs of biological therapeutics while improving healthcare outcomes. As part of its environmental, social and governance commitment, the company advances the health of patients, people, and the planet to achieve key UN Sustainable Development Goals.

Biocon Limited has received a credit rating reaffirmation from CRISIL Ratings Limited, maintaining its strong creditworthiness profile. The pharmaceutical company informed stock exchanges about this development as part of its regulatory disclosure obligations under SEBI regulations.

Credit Rating Details

CRISIL has reaffirmed Biocon's credit ratings across its bank facilities, demonstrating confidence in the company's financial stability and repayment capacity. The rating action covers the company's total bank loan facilities of ₹250.00 crores.

Regulatory Compliance

The rating reaffirmation was disclosed pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. This regulation mandates listed companies to inform stock exchanges about material events that could impact investor decisions.

Biocon has made the rating information available on both CRISIL's official website and the company's corporate website at www.biocon.com , ensuring transparency and easy access for stakeholders.

Significance of Rating Reaffirmation

The CRISIL AA/Stable rating indicates high safety regarding timely servicing of financial obligations, with very low credit risk. The stable outlook suggests that the rating is unlikely to change in the near term. The A1+ short-term rating reflects the highest degree of safety regarding timely payment of short-term debt obligations.

This rating reaffirmation reinforces Biocon's strong financial position in the pharmaceutical sector and provides confidence to lenders and investors about the company's creditworthiness and ability to meet its financial commitments.